miércoles, 7 de octubre de 2026

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· July 10, 2026

Pepeto Passes $10.4 Million While the BNB Price Prediction Target $2,000 As Best Crypto To Buy

View original at globenewswire.com

Pepeto Passes $10.4 Million While the BNB Price Prediction Target $2,000 As Best Crypto To Buy DUBAI, United Arab Emirates, July 10, 2026 (GLOBE NEWSWIRE) -- Crypto presale Pepeto moved past $10.431 million, and traction like that in a red market raises one question…

Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

Pepeto has 420 trillion tokens priced at $0.0000001881, with 30% of supply allocated to presale tokens; a climb to a $300 million market cap would mean roughly 50x, turning $5,000 into $250,000, and matching PEPE's peak would push well past 100x.
60% confidence
BNB is trading near $577.
60% confidence
A run from $577 to $2,000 for BNB is about a 3.5x return, turning $1,000 into roughly $3,500.
60% confidence
Pepeto sits first among crypto presales this year by capital raised, following the exchange token model.
60% confidence
The top BNB price prediction for a full bull cycle is $2,060.
60% confidence
Early BNB buyers entered the 2017 ICO at $0.10 per token when it had barely any market value.
60% confidence
Pepeto built a zero-fee exchange running on its own token, plus a cross-chain bridge linking Ethereum, BNB Chain, and Solana with no gas cost.
60% confidence

Data points we hold from this source

Pepeto · token price	0.0000001881 USD
Pepeto · funding raised	10.41 USD

Lo que sabemos · la inteligencia detrás de esta página

En vivo desde el sustrato

Lo que estamos viendo

Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs

Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.

Nuestra lectura de los datos ›

Señales que seguimos

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patrones que observamos ›

Donde las fuentes discrepan

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

Señalamos los conflictos abiertamente ›

Verificado recientemente

✓ Verificado con la fuente original

4,986

hechos rastreados a su fuente — y señalamos los que no se sostienen.

101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados

Consulta estos datos → isubstrate.com

Pepeto Passes $10.4 Million While the BNB Price Prediction Target $2,000 As Best Crypto To Buy — Source | Via News | es.VIA.NEWS